TDSGF (Telo Genomics) EBIT per Share: $-0.02 (TTM As of Mar. 2026)


What is Telo Genomics EBIT per Share?

Telo Genomics TDSGF EBIT per Share is $-0.02 as of Mar. 2026. The stock has 2 warning signs investors should review. Among 168 Medical Diagnostics & Research companies, Telo Genomics ranks worse than 61.31% on this metric.

Telo Genomics's EBIT per Share for the three months ended in Mar. 2026 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.02.

During the past 3 years, the average EBIT per Share Growth Rate was 4.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 1.30% per year. During the past 10 years, the average EBIT per Share Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Telo Genomics's EBIT per Share or its related term are showing as below:

TDSGF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -162.3   Med: 3.05   Max: 64.4
Current: 4.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Telo Genomics was 64.40% per year. The lowest was -162.30% per year. And the median was 3.05% per year.

TDSGF's 3-Year EBIT Growth Rate is ranked worse than
61.31% of 168 companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75 vs TDSGF: 4.90

Telo Genomics's EBIT for the three months ended in Mar. 2026 was $-0.42 Mil.

Telo Genomics  (OTCPK:TDSGF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Telo Genomics EBIT per Share Related Terms

Telo Genomics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Telo Genomics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics EBIT per Share Chart

Telo Genomics Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.03 -0.04 -0.03 -0.02

Telo Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 -0.00 -0.00

Telo Genomics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Telo Genomics's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.977/87.743
=-0.02

Telo Genomics's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.42/100.430
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.02 mean?
Telo Genomics (TDSGF) has a EBIT per Share of $-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Telo Genomics and its competitors. According to the industry distribution chart, Telo Genomics ranks #103 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 61.3%.
Is Telo Genomics' EBIT per Share too high?
Telo Genomics' current EBIT per Share is $-0.02. Based on the distribution chart, Telo Genomics ranks #103 out of 168 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Telo Genomics' EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #103 out of 168 companies for EBIT per Share. This places Telo Genomics in the lower half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Telo Genomics and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telo Genomics's current EBIT per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current EBIT per Share of $-0.02. The current EBIT per Share is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current EBIT per Share is $-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.